Alnylam Pharmaceuticals, Inc. (ALNY) — Fair Value Analysis

Base-case fair value (P50): $275.16 · Current price: $237.10 · Verdict: Undervalued

The Verdict on ALNY

Alnylam Pharmaceuticals Inc (ALNY) is currently assessed as Fairly Valued based on our proprietary Monte Carlo simulations. While the initial question might be "Is ALNY overvalued?", our analysis indicates the stock trades close to its intrinsic value. The current price of $237.10 is positioned below our median fair value (P50) of $275.16, suggesting a potential +16.1% upside to its probabilistic fair value. This robust simulation, drawing from thousands of forward scenarios, indicates that ALNY's current market valuation largely reflects its fundamental prospects without significant over-extension, despite offering some headroom for growth. The Monte Carlo method provides a comprehensive view beyond simple point estimates, anchoring ALNY's valuation within a likely distribution of future outcomes.

How ALNY stacks up against peers

When considering Alnylam Pharmaceuticals Inc (ALNY) in comparison to its sector peers, our analysis places its operational and financial health in the average quality tier. This assessment, factored into the Monte Carlo simulations that derive the $275.16 fair value, implies a balanced risk-reward profile within its competitive landscape. An average quality tier indicates that ALNY exhibits neither significant operational red flags nor outstanding competitive advantages compared to the broader sector, suggesting that its $237.10 accurately reflects this competitive positioning. While there's a +16.1% gap to our P50 fair value, this is within the expected range for a fairly valued stock of average quality.

What this means for investors

For investors tracking Alnylam Pharmaceuticals Inc (ALNY), the Fairly Valued verdict, supported by a median fair value of $275.16 against the current $237.10, suggests that present pricing offers a reasonable entry point for long-term holders, rather than indicating an overvalued asset. The +16.1% potential points to a modest expected return if the stock converges towards its probabilistic fair value. Investors seeking to understand the full range of potential outcomes, including specific bear-case downside scenarios and bull-case upside targets, can leverage FairCurve. Sign up for a free FairCurve account to see the full bear/bull distribution and track ALNY's fair value as new fundamentals are released.